Delving into the Latest Updates on Suzhou Kanger Biomedical Co. Ltd. with Synapse

Overview

Tags

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CAMP(Cathelicidin antimicrobial peptide)	1

Primary objective: To evaluate the safety and tolerability of a single dose of Bungarus antimicrobial peptide vaginal effervescent tablets in healthy adult female subjects. Secondary objective: To evaluate the preliminary human pharmacokinetic characteristics of a single dose of Bungarus antimicrobial peptide vaginal effervescent tablets in healthy adult female subjects.

Start Date03 Nov 2021

Sponsor / Collaborator

Suzhou Kanger Biomedical Co. Ltd.

[+1]

100 Clinical Results associated with Suzhou Kanger Biomedical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Kanger Biomedical Co. Ltd.

Login to view more data

100 Deals associated with Suzhou Kanger Biomedical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Kanger Biomedical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data